STUDY QUESTION: Does administration of corifollitropin alfa followed by highly purified (hp) HMG result in higher ongoing pregnancy rates compared with daily recombinant FSH (rFSH) in young poor responders?
cardiac activity at 9-10 weeks of gestation). Secondary outcomes included embryo cryopreservation rates, clinical and biochemical pregnancy rates and number of oocytes retrieved.
MAIN RESULTS AND THE ROLE OF CHANCE:
Overall, 152 poor ovarian responders defined by the 'Bologna' criteria were included in the study. Using an intention-to treat analysis, the ongoing pregnancy rates did not differ significantly between Group A 11/77 (14.3%) and Group B 11/70 (15.7%) , absolute difference: −0.4 (−11.5 to 10.8), OR = 0.9 (0.4-2.4). Biochemical and clinical pregnancy rates, live birth rates and the number of oocytes retrieved were also comparable between the two groups. Nevertheless, more patients in the corifollitropin alfa group had cryopreserved embryos compared to the rFSH group [22 (28.6%) versus 10 (14.3%), OR = 2.4 (1.01-5.5)]. Incidentally, Asian patients had significantly lower cancellation rates compared to European poor responders [2/64 (3.1%) versus 17/83 (20.4%), OR = 0.12 (0.03-0.5)]. This discrepancy could be explained by the fact that Asian women were better prognosis patients than European patients, with significantly lower FSH [9.8 (5.3) versus 11.5 (5.4), P = 0.017] and significantly higher AMH [1.1 (0.9) versus 0.4 (0.3), P-value <0.001] levels.
LIMITATIONS, REASONS FOR CAUTION:
Ongoing pregnancy rates close to 14% for both treatment groups differ significantly from the hypothesized primary outcome rates used in the power calculation. Therefore, our randomized trial might have been underpowered to detect smaller differences. The use of multiple secondary outcomes and multiple comparisons could have increased a Type 1 error. Finally, although the chance of selection biases remains low given the nature of the infertile population, the open-label design could have been a limitation.
WIDER IMPLICATIONS OF THE FINDINGS:
Poor ovarian response represents a challenge and although a specific protocol may have increased the number of cryopreserved embryos, no difference was observed in ongoing pregnancy rates. Our study, being one of the largest RCTs in 'Bologna' criteria poor responders, highlights that baseline characteristics may play a crucial role in clinical prognosis of this population. Given that ovarian stimulation using novel protocols does not seem to significantly increase pregnancy rates even in young women, we suggest that future clinical research should focus on increasing the number of recruitable follicles and on oocyte quality rather than evaluating different stimulation protocols. 
Introduction
Poor ovarian response remains one of the main therapeutic challenges in women undergoing ovarian stimulation, with an incidence ranging from 9 to 24% (Ubaldi et al., 2005; Patrizio et al., 2015) . Despite the use of different treatment regimens for the management of this particular cohort of patients, no single protocol is considered to be unequivocally effective (Papathanasiou et al., 2016) .
Given the variability in the arbitrary definitions used for poor ovarian response up to 2011 (Polyzos and Devroey, 2011) , the European Society of Human Reproduction and Embryology developed a new definition, the so called 'Bologna' criteria, in order to refine this group of patients and a pathway to overcome limitations in the interpretation of the relevant literature (Ferraretti et al., 2011) . Nevertheless, the biggest challenge remains the very low live birth rates of 6% per cycle that have been reported in Bologna criteria poor responders irrespective of age and treatment protocol used Busnelli et al., 2015; La Marca et al., 2015) .
In spite of the uniform prognosis among Bologna criteria poor responders, concerns have been raised that a degree of heterogeneity remains in the actual definition, given that the prognostic effect of individual factors is still unclear, particularly for the young poor responder group (Oudendijk et al., 2012; Younis, 2012) . The latter should definitely be taken carefully into consideration, especially if we consider the negative impact of age not only on the percentage of genetically abnormal embryos (Franasiak et al., 2014) , but also on live birth rates, irrespective of the level of ovarian response (McLernon et al., 2016) .
Taking into account the available evidence showing disappointing results in older poor responders (van Rooij et al., 2003) , it seems that clinical trials may preferably focus on younger patients to assess new treatment modalities, if any benefit is to be anticipated for this poor prognosis population.
The rationale for conducting the current randomized trial comes from our previous pilot study demonstrating promising results in terms of pregnancy rates with the administration of corifollitropin alpha followed by highly purified (hp) human menopausal gonadotropin (hp-HMG) in women <40 years of age, fulfilling the Bologna criteria (Polyzos et al., 2013b) . We considered that an ongoing pregnancy rate of 28% observed in a previous study should not be overlooked, and that this novel protocol needed be tested in a well-designed randomized trial-the 'COMPORT' study (Polyzos et al., 2013a) , the only way to compare medical interventions.
Materials and Methods
An institutional review board approval was obtained to perform the study from the Ethical Committee of Universitair Ziekenhuis Brussel (BUN 143201317805), and also from the local Ethical Committee of the University of Medicine and Pharmacy HCMC Vietnam (03.1/15/DD-BVMD). All patients gave written informed consent in order to participate in this study. The EUDRACT number of the trial was 2013-000583-29, and the study was registered in clinicaltrials.gov (NCT01816321).
Trial design
This study ('COMPORT' RCT) was a multicenter, open-label, phase III, superiority, randomized trial using a parallel two-arm design.
Participants
The study included 152 patients younger than 40 years old, fulfilling the Bologna criteria for poor ovarian response, from one tertiary referral centre in Europe (Universitair Ziekenhuis Brussel, Brussels, Belgium) and one tertiary referral centre in Asia (IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam). Patients underwent ovarian stimulation for ICSI from March 2013 to May 2016. Patients could participate in the study only once. AMH was measured in a previous cycle, irrespective of the cycle day. All samples were measured with the Gen II Beckman Coulter AMH ELISA kit. The cut-off of AMH < 1.1 ng/ml for prediction of poor response was used, as already reported (Ferraretti et al., 2011) . AFC was measured on Day 2-4 of a previous cycle and the cutoff < 7 was used to predict poor ovarian response (Ferraretti et al., 2011) .
Exclusion criteria included: uterine abnormalities, recent history of any current untreated endocrine abnormality, unilateral or bilateral hydrosalpinx (visible on ultrasound, unless clipped), contraindications for the use of gonadotropins and history of untreated endocrine disease.
Interventions
Eligible patients who agreed to participate were randomized to either administration of corifollitropin alfa followed by hp-HMG (Group A) or to recombinant follicle stimulating hormone (rFSH) (Group B) in a gonadotropin-releasing hormone (GnRH) antagonist protocol ( Figure 1 ).
Investigational group (Group A)
On Day 2 of the menstrual cycle, a single subcutaneous (SC) injection of 150 μg corifollitropin alfa was administered (Stimulation Day 1). Starting on Figure 1 Schematic presentation of the treatment arms. OPU, oocyte pick-up; ET, embryo transfer. (A) corifollitropin alfa followed by hp-HMG in a GnRH antagonist protocol. (B) corifollitropin alfa followed followed by rFSH in a GnRH antagonist protocol.
Stimulation Day 6, the subject received a daily SC injection of 0.25 mg ganirelix up to and including the day of hCG administration to prevent premature luteinizing hormone (LH) surges. From Stimulation Day 8 onwards, treatment also included a daily SC dose of hp-HMG (300 IU/day) up to the day of hCG administration.
Reference group (Group B)
On Day 2 of the menstrual cycle, a daily SC dose of rFSH (300 IU/day) was administered up to the day of hCG administration (Stimulation Day 1). Starting on Stimulation Day 6, the subject also received a daily SC injection of 0.25 mg ganirelix up to and including the day of hCG administration to prevent premature LH surges.
Both groups
If at Stimulation Day 8-10 not at least one follicle ≥ 11 mm was visible on ultrasound, the cycle was cancelled due to insufficient ovarian response; in case of a monofollicular development, the patient was allowed to proceed to oocyte retrieval.
As soon as two follicles ≥ 17 mm were observed by ultrasound, hCG 10 000 IU was administered the same day or the day after to induce final oocyte maturation. About 34-36 hours thereafter, oocyte pick-up followed by ICSI was performed. On Day 3 after oocyte pick-up, a maximum of three embryos were transferred. Embryo quality was based on the Istanbul consensus workshop on embryo assessment: top quality embryos on Day three had at least seven blastomeres, with even cell sizes and no more than 10% fragmentation, as previously described (De Vos et al., 2013) . Supernumerary embryos were vitrified on Day 3. Luteal phase support with progesterone tablets (200 mg × 3, intravaginally), was initiated on the day of oocyte pick-up or the day thereafter and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 14 days after oocyte pick-up.
Outcomes
The primary outcome was ongoing pregnancy rate, defined as the presence of an intrauterine gestational sac with an embryonic pole with cardiac activity at 9-10 weeks of gestation (Shapiro et al., 2011) .
Secondary outcomes included the rates of clinical pregnancy (presence of intrauterine gestational sac at 7 weeks of gestation) and biochemical pregnancy (positive pregnancy test 2 weeks after embryo transfer) and number of oocytes retrieved.
Other efficacy endpoints included the number of cycles with frozen supernumerary embryos, cancellation rate due to poor ovarian response, number of cycles reaching the stage of embryo transfer and percentage of top quality embryos transferred. Post-trial information included the live birth rate.
Sample size calculation
Sample size calculation was performed considering results from a previous pilot study with corifollitropin alfa followed by hp-HMG and results from a large series of young poor responders in our centre.
Based on the fact that the pilot study Polyzos et al. (2013b) demonstrated ongoing pregnancy rates of 28% per patient in young poor responders treated with corifollitropin alfa followed by hp-HMG, whereas standard of care stimulation in our centre has shown an ongoing pregnancy rate of 8.5% in this group, we hypothesized that a sample size of 150 patients (75 in Group A and 75 patients in Group B) is essential in order to have 85% power to detect a difference of 19.5% in ongoing pregnancy rates under the null hypothesis that in both groups the pregnancy rates were assumed to be 8.5% and the alternative hypothesis that the pregnancy rates in the corifollitropin alfa/hp-HMG group would be 28%, using a two-sided Fisher exact test with a significance level (alpha) of 0.05.
Randomization and allocation of patients to study groups
Patients were randomized to either corifollitropin alfa followed by hp-HMG (Group A), or to rFSH (Group B) only after patient eligibility was established and patient consent was obtained. Randomization sequence and allocation was created using a computer generated randomization list, stratified by centre, using 1:1 allocation.
Statistical analysis
Analyses were performed in intent-to-treat fashion and per-protocol. Consequently, in the intention-to-treat analysis, all patients were included in the final analysis as long as after fulfilment of the inclusion criteria they were randomly allocated to one of the treatment groups, whereas the per-protocol analysis included only those patients who completed the treatment originally allocated.
Descriptive summary measures expressed as mean (standard deviation) were used for continuous variables and number (percentage) for categorical variables, in order to provide a summary estimate of patient demographics and baseline characteristics, in line with the CONSORT statement (www.consort-statement.org). For the primary outcome (ongoing pregnancy rates), the secondary outcomes and the other efficacy endpoints, results were analysed by using a two-sided chi-square test or Fisher exact test as appropriate, with a level of significance 0.05. For continuous variables, parametric (independent t-test) or non-parametric (Mann-Whitney test) tests were used depending on the normality of the distribution. Normality was examined by the use of the Shapiro-Wilk test. Results were also summarized with 95% CIs both in absolute terms and as Mantel-Haenszel odds ratios for binomial outcomes and 95% difference of means for continuous outcomes, as suggested by the CONSORT statement. Mantel-Haenszel odds ratios were used in order to account for the stratification by centre.
Additional analyses were performed for different stages (e.g. ongoing pregnancy rates were also calculated only for those subjects who reached embryo transfer). Furthermore, analyses in an exploratory fashion for the primary and secondary outcomes were performed by centre.
All analyses were performed in STATA 13 Statistical software.
Results
Overall, 152 poor ovarian responders defined by the Bologna criteria were included in the study (Fig. 2) . Baseline characteristics of the patients randomized to the two groups are presented in Table I .
Primary outcome measure
Using an intention-to-treat analysis, the ongoing pregnancy rates did not differ significantly between Group A 11/77 (14.3%) and Group B 11/75 (14.7%), absolute difference: −0.4 (−11.5 to 10.8), OR = 0.9-(0.4-2.4) ( Table II) . Using a per-protocol analysis, excluding five patients (three who were allocated to a treatment arm, but for unknown reasons never started the treatment and two protocol violations), the percentage of ongoing pregnancy rates was still not significantly different between the two study arms, 11/77 (14.3%) for Group A versus 11/70 (15.7%) for Group B, absolute difference: −1.5 (−13-10), OR = 0.9(0.4-2.3) (Table II) .
Secondary outcome and other efficacy endpoints measures
Secondary outcomes and other efficacy endpoints results are also presented in Table II pregnancy rates were comparable between the two groups, OR = 0.7(0.3-1.6) and OR = 0.8(0.3-2), respectively. The number of oocytes and the number of metaphase II oocytes did not differ significantly between Group A and Group B.
Interestingly, more patients in the corifollitropin group had cryopreserved embryos compared to rFSH [22 (28.6%) versus 10 (14.3%), OR = 2.4 (1.01-5.5).
The cycle cancellation rates and the number of cycles reaching the stage of embryo transfer were comparable between groups. No significant differences were observed between hp-HMG following corifollitropin alpha and rFSH regarding the number of embryos transferred and the percentage of top quality embryos transferred among patients with embryo transfer.
Ongoing pregnancy rates remained non-significant when the analysis was performed only for patients having embryo transfer.
Post-trial information
Given that the recruitment of patients ended in May 2016, live birth rates are also provided, showing no significant differences between the treatment arms [10 (12.9%) versus 10 (14.2%), OR = 0.9 (0.3-2.3)] (Table II) .
Additional analyses per centre performed in an exploratory fashion
Primary, secondary and other efficacy outcomes were also analysed per centre (Supplementary Table S1 ). In the first centre (Belgium), 45 patients were randomized to Group A and 38 to Group B. Overall, for the 83 randomized patients in the first centre, no significant difference was detected in the primary and all the secondary and efficacy outcomes between groups. Similarly, in the second centre (Vietnam), for the 64 randomized patients (32 in Group A and 32 in Group B), results were similar between the two treatment arms. However, interestingly, poor responders from the European and the Asian centre had different ovarian response patterns.
Furthermore, overall, poor responders from the Vietnamese centre performed better than poor responders from the Belgian centre, regardless of the randomization arm. In particular, 12/64 (18.7%) Asian versus 10/83 (8.3%) European women had an ongoing pregnancy. This discrepancy could be explained by the fact that Asian women were of better prognosis, with significantly lower FSH [9.8 (5.3) versus 11.5 (5.4), P = 0.017], significantly higher AMH [1.1 (0.9) versus 0.4 (0.3), P < 0.001] and lower number of previous IVF/ICSI attempts [2.2 (1.6) versus 1.6 (1), P = 0.003] (Supplementary Table SII ).
Discussion
The current randomized trial is one of the largest studies performed in poor responders according to the Bologna criteria, and the first evaluating the superiority of administrating corifollitropin alfa followed by hp-HMG versus daily rFSH. According to our results, corifollitropin alfa followed by hp-HMG is not superior to daily injection of 300 IU of rFSH in a GnRH antagonist protocol, since comparable ongoing pregnancy rates were observed between treatment groups. Nevertheless, patients allocated to the corifollitropin alfa group had significantly more supernumerary embryos compared to rFSH group.
Previous large randomized trials in women with normal ovarian response have demonstrated that corifollitropin alfa as compared with daily rFSH, may result in comparable pregnancy rates with a potential increase in the number of oocytes retrieved (Devroey et al., 2009; Corifollitropin alfa Ensure Study, 2010; Boostanfar et al., 2015) . In order to investigate the efficacy of this new gonadotropin in women with poor ovarian response, preliminary pilot studies have been conducted in this special infertile population. Based on these results, corifollitropin alfa followed by the administration of hp-HMG in a GnRH antagonist protocol was found to be beneficial in terms of pregnancy rates in women younger than 40 years, whereas results remained low for older women regardless of the protocol or the gonadotropins used (Polyzos et al., 2013b (Polyzos et al., , c, 2015 . Consequently and based on large retrospective analyses showing that in Bologna criteria poor responders live birth rates are low and can significantly improve if we manage to increase the number of oocyte retrieved , we set out to perform the COMPORT trial, in order to validate the results observed by the initial preliminary studies. However, the current study failed to corroborate the initial results of our previous pilot study, showing ongoing pregnancy rates of 28% in young poor responders (Polyzos et al., 2013b) .
In an attempt to explain the discrepancies between our preliminary data (Polyzos et al., 2013b) and the current randomized trial, several explanations may be given. First and most important, it is well established that observational data are linked to selection and confounding biases which may substantially affect the validity of the results (Ioannidis, 2005) . This may have certainly been the case in our early trial and for this reason it was clearly highlighted in our pilot studies that these data were preliminary and in need of further validation through well-designed RCTs like the present trial.
The 'Bologna' criteria was the first systematic and realistic attempt by a scientific committee to define poor ovarian responders in order to overcome methodological drawbacks derived by studies, using 'random definitions' or meta-analyses using an assortment of definitions, which could hamper the external validity of the provided results (Polyzos and Devroey, 2011; . Nevertheless, the 'Bologna' criteria have been criticized, especially because the various mechanisms of ovarian aging have not been completely elucidated (Frydman, 2011; Younis, 2012) . Bologna criteria may include heterogeneous subpopulations with diverse baseline characteristics and different clinical prognosis, as clinical prognosis is related to both the number of recruited oocytes (reduced ovarian reserves) and to baseline characteristics, such as age, which affects oocyte quality and quantity (Papathanasiou, 2014) . Nevertheless, other characteristics in recurrent poor responders may be present and these women cannot be homogeneous regarding pregnancy outcome, when age is taken into account (Oudendijk et al., 2012; Ferraretti and Gianaroli, 2014) . As shown in the current RCT, despite the fact that all the patients fulfilled the Bologna criteria, Asian patients had significantly higher ovarian reserve markers and lower number of previous IVF/ICSI cycles. The diversity in patients' ethnicity may be the third reason to explain the discrepancy between the preliminary data and the COMPORT trial. After stratification by centre, results were replicated for the primary and secondary outcomes showing no significance, although the treatment effect direction were opposite between European and Asian women. However, this discrepancy could simply be a random finding which can be justified by the sparse data and the small number of randomized Asian patients.
Finally, despite the fact that we failed to find any significant difference in our primary outcome, we need to underscore that according to our results, corifollitropin alpfa followed by hp-HMG resulted in more supernumerary embryos in both European and Asian young poor responders. Given that the cumulative live birth rate is a highly relevant outcome for patients value, if of course this is associated with an increase in cumulative live birth rates in this population.
The major strength of our study lies in a robust design, as it represents one of the largest randomized trials conducted in poor ovarian responders according to Bologna criteria, and this should be emphasized given the genuine difficulty in recruiting poor responders in randomized trials (Pandian et al., 2010) .
Nevertheless, despite the robustness of the study design, readers may criticize the large difference our study was aiming at to find between groups, despite the fact that this was based on preliminary published data. This is indeed one of the major limitations of our randomized trial given that the observed ongoing pregnancy rates close to 14% for both treatment groups differed significantly from the hypothesized primary outcome rates used in the power calculation. Therefore, our randomized trial might have been underpowered to detect smaller differences. Finally, it would be challenging from a practical and logistic point of view to blind physicians/patients, given that in one group corifollitropin alfa was administrated for ovarian stimulation i.e a single injection for 7 days. However, even if blinded RCTs are considered the gold standard of evidence based medicine, it is rather unlikely that the open-label design used in our RCT would have induced any selection bias in this poor prognosis infertile population.
In conclusion, treatment of poor ovarian responders remains difficult for clinicians, as at the end of the day none of the available treatment options seem to be of benefit for this group of patients. Our randomized trial adds further to the available evidence by demonstrating that the administration of corifollitropin alfa followed by hp-HMG does not increase pregnancy rates as compared with rFSH in a GnRH antagonist protocol. However, it results in a significantly higher number of supernumerary embryos. On the other hand, the baseline characteristics of poor responders may play an important role in their clinical prognosis. Our aim is not to reject the definition of poor responders according to 'Bologna' criteria, especially if we consider that the 'Bologna' criteria did not presume to distinguish between alterations in oocyte quantity versus oocyte quality. Oocyte quality still remains the biggest challenge for reproductive science with sparse evidence being published in recent years, mainly because the factors responsible for cellular health and competence are poorly understood and investigated (Gosden and Johnson, 2016) . In this regard, we believe that there is still room for improvement in the management of poor responders, and clinical research based on well-designed randomized trials should continue in this poor prognosis population , potentially focusing on how to increase the number of recruitable follicles and oocyte quality rather than evaluating different stimulation protocols.
Supplementary data
Supplementary data are available at Human Reproduction online.
